Fig. 5From: Restrictive IgG antibody response against mutated citrullinated vimentin predicts response to rituximab in patients with rheumatoid arthritisIndividual IgA anti-MCV titer courses of responders and non-responders upon RTX treatment with mean titer change (red). Responders showed a greater tendency to reduce their initial titer from baseline to week 24 upon RTX treatment compared to non-responders, who rather remained stableBack to article page